Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADV7103 in Primary Distal Renal Tubular Acidosis (ARENA 2)
NCT03831152Phase 3Withdrawn
- Sponsor
- Advicenne
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Sibnayal in distal renal tubular acidosis (dRTA), sponsored by Advicenne. Primary endpoint: Treatment-Emergent Adverse Events at 30 months. Planned start Dec 2023; status: withdrawn.
02
Drugs
Sibnayal
03
Conditions
distal renal tubular acidosis (dRTA)
Beyond the preview
Go deeper on NCT03831152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831152.